Stuart Schreiber

From Wikipedia, the free encyclopedia

You have new messages (last change).
Stuart Schreiber
Stuart Schreiber

Stuart L. Schreiber (b. February 6, 1956) is a scientist at Harvard University and the Broad Institute of Harvard and MIT. He has been a pioneer in a field of research named chemical biology for over 20 years. His name is closely associated with the increasingly common use of small molecules as probes of biology and medicine. Small molecules are the molecules of life most associated with dynamic information flow; these work in concert with the macromolecules (DNA, RNA, proteins) that are the basis for inherited information flow. During the 1980s and '90s, he provided dramatic advances in biology using this approach, and, in the past ten years, his systematization efforts have made this one of the fastest growing areas of life-science research.

Contents

[edit] Education and Training.

Schreiber obtained a Bachelor of Science degree in Chemistry from the University of Virginia, after which he entered Harvard University as a Graduate Student in Chemistry. He joined the research group of Robert B. Woodward and after Woodward's death continued his studies under the supervision of Yoshito Kishi. In 1980 he joined the faculty of Yale University as an Assistant Professor in Chemistry.

[edit] Key discoveries, 1980s and 1990s

Schreiber started his research work in Organic Synthesis, pioneering concepts such as the use of photocycloaddition to establish stereochemistry in complex molecules, the fragmentation of hydroperoxides to produce macrolides, ancillary stereocontrol, group selectivity and two-directional synthesis. Notable accomplishments include the total syntheses of complex natural products such as talaromycin B, asteltoxin, avenaciolide, gloeosporone, hikizimicin, mycoticin A, epoxydictymene and the immunosuppressant FK-506. Following his co-discovery of the FK506-binding protein FKBP12 in 1988, Schreiber reported that the small molecules FK506 and cyclosporin inhibit the activity of the phosphatase calcineurin by forming the ternary complexes FKBP12-FK506-calcineurin and cyclophilin-cyclosporin-calcineurin.[1] This work, together with work by Gerald Crabtree at Stanford University concerning the NFAT proteins, led to the elucidation of the calcium-calcineurin-NFAT signaling pathway.[2] This landmark discovery, an early example of defining an entire cellular signaling pathway from the cell surface to the nucleus, can be appreciated when it is considered that the Ras-Raf-MAPK pathway was not elucidated for another year.

In 1993 Schreiber and Crabtree developed "small-molecule dimerizers", which provide small-molecule activation over numerous signaling molecules and pathways (e.g., the Fas, insulin, TGFβ and T-cell receptors[3][4]) through proximity effects. Schreiber and Crabtree demonstrated that small molecules could activate a signaling pathway in an animal with temporal and spatial control.[5] Dimerizer kits have been distributed freely to (as of February, 2005) 898 laboratories at 395 different institutions worldwide, resulting thus far in over 250 peer-reviewed publications from the scientific community. Its promise in gene therapy has been highlighted by the ability of a small molecule to induce production of erythropoeitin (EPO) in primates without diminution over, thus far, a six-year period, and more recently in phase II human clinical trials for treatment of graft-vs-host disease (ARIAD Pharmaceuticals, Inc.).

In 1994, Schreiber discovered that the small molecule rapamycin simultaneously binds FKBP12 and mTOR (originally named FKBP12-rapamycin binding protein, FRAP).[6] Using diversity-oriented synthesis and small-molecule screening, Schreiber helped illuminate the nutrient-response signaling network involving TOR proteins in yeast and mTOR in mammalian cells. Small molecules such as uretupamine[7] and rapamycin were shown to be particularly effective in revealing the ability of proteins such as mTOR, Tor1p, Tor2p, and Ure2p to receive multiple inputs and to process them appropriately towards multiple outputs (in analogy to multi-channel processors). Several pharmaceutical companies are now targeting the nutrient-signaling network for the treatment of several forms of cancer, including solid tumors.[8]

In 1996 Schreiber used the small molecules trapoxin and depudecin to characterize molecularly the histone deacetylases (HDACs).[9] Prior to Schreiber’s work in this area, the HDAC proteins had not been isolated – despite many attempts by others in the field who had been inspired by Allfrey's detection of the enzymatic activity in cell extracts over 30 years earlier. Co-incident with the HDAC discovery, David Allis and colleagues reported their discovery of the histone acetyltransferases (HATs). These two contributions catalyzed much research in this area, eventually leading to the characterization of numerous histone-modifying enzymes, their resulting histone “marks”, and numerous proteins that bind to these marks. By taking a global approach to understanding chromatin function, Schreiber proposed a “signaling network model” of chromatin and compared it to an alternative view, the “histone code hypothesis” presented by Strahl and Allis.[10] The work by chromatin researchers has shined a bright light on chromatin as a key regulatory element rather than simply a structural element.

[edit] Advancing chemical biology through the 1990s and 2000s

During the past 10 years, Schreiber has attempted to systematize the application of small molecules to biology through the development of diversity-oriented synthesis (DOS)[11], chemical genetics[12], and ChemBank.[13] Schreiber has shown that DOS can produce small molecules distributed in defined ways in chemical space by virtue of their different skeletons and stereochemistry, and that it can provide chemical handles on products anticipating the need for follow-up chemistry using, for example, combinatorial synthesis. DOS pathways and new techniques for small-molecule screening [14][15][16] provided many new insights into biology. For example, Schreiber and collaborator Tim Mitchison used cytoblot screening to discover monastrol – the first small-molecule inhibitor of mitosis that does not target tubulin. Monastrol was shown to inhibit kinesin-5, a motor protein[17] and was used to gain new insights into the functions of kinesin-5. This work led pharmaceutical company Merck, among others, to pursue anti-cancer drugs that target human kinesin-5. Small-molecule probes of histone and tubulin deacetylases, transcription factors, cytoplasmic anchoring proteins, developmental signaling proteins (e.g., histacin, tubacin, haptamide, uretupamine, concentramide, and calmodulophilin), among many others, have been discovered in the Schreiber lab using diversity-oriented synthesis and chemical genetics. Multidimensional screening was introduced in 2002 and has provided insights into tumorigenesis, cell polarity, and chemical space, among others.[18] More than 100 laboratories from over 30 institutions have performed small-molecule screens at the screening center he developed ( Broad Chemical Biology (BCB), formerly the Harvard ICCB), leading to many small-molecule probes (81 probes were reported in the 2004 literature alone) and insights into biology. To facilitate the open sharing of small-molecule-based insights, Schreiber pioneered the development of the assay-data repository and analysis environment named ChemBank, which was launched on the Internet in 2003. A complete rework of ChemBank (v2.0), which makes accessible to the public results and analyses from 1,209 small-molecule screens that have yielded 87 million measurements, was re-launched in March 2006.

Schreiber’s laboratory has served as a focal point for the field of chemical biology, first by the ad hoc use of small molecules to study primarily three specific areas of biology, and then through the more general application of small molecules in biomedical research. As a principal architect of chemical biology, he has influenced the public and private research communities. Programs at other universities have been established in chemical biology as well as efforts to hire faculty in the area of chemical biology – often from his laboratory. Academic screening centers have been created that emulate the Broad Institute Chemical Biology Program; in the U.S., there has been a nationwide effort to expand this capability via the government-sponsored NIH Road Map. Chemistry departments have changed their names to include the term chemical biology and new journals have been introduced (Chemistry & Biology, ChemBioChem, Nature Chemical Biology, ACS Chemical Biology) to cover the field. Schreiber has been involved in the founding of three biopharmaceutical companies based on chemical biology principles: Vertex Pharmaceuticals, Inc. (VRTX), Ariad Pharmaceuticals, Inc. (ARIA), and privately held Infinity Pharmaceuticals, Inc. These companies have produced new medicines in several areas of disease, including AIDS and cancer.

[edit] Selected Awards

  • Award in Pure Chemistry, ACS (1989). "For pioneering investigations into the synthesis and mode of action of natural products."
  • Ciba-Geigy Drew Award for Biomedical Research: Molecular Basis for Immune Regulation (1992). "For the discovery of immunophilins and for his role in elucidating the calcium-calcineurin-NFAT signaling pathway."
  • Leo Hendrik Baekeland Award, North Jersey Section of ACS (1993). "For outstanding achievement in creative chemistry."
  • Eli Lilly Award in Biological Chemistry, ACS (1993). "For fundamental research in biological chemistry."
  • American Chemical Society Award in Synthetic Organic Chemistry (1994). "For creative accomplishments at the interface of organic synthesis, molecular biology, and cell biology as exemplified by landmark discoveries in the immunophilin area."
  • George Ledlie Prize (Harvard University) (1994). "For his research which has profoundly influenced out understanding of the chemistry of cell biology and illuminated fundamental processes of molecular recognition and signaling in cell biology."
  • Harrison Howe Award (1995). "In recognition of accomplishments in the synthesis of complex organic molecules, progress in understanding the immunosuppressant action of FK506, and innovation in molecular recognition and its role in intracellular signaling."
  • Warren Triennial Award (shared with Leland Hartwell) (1995). "For creating a new field in organic chemistry, what Phil Sharp has coined 'chemical cell biology.' In these studies, small molecules have been synthesized and used to understand and control signal transduction pathways. Schreiber has made it possible to generalize the use of small molecules to study protein function in analogy to the use of mutations in genetics. This approach has illuminated fundamental processes in cell biology and has great promise in medicine."
  • Tetrahedron Prize for Creativity in Organic Chemistry (1997). "For his fundamental contributions to chemical synthesis with biological and medicinal implications."
  • ACS Award for Bioorganic Chemistry (2000). "For his development of the field of chemical genetics, where small molecules are used to dissect the circuitry of cells using genetic-like screens."
  • William H. Nichols Medal (2001). "For contributions toward understanding the chemistry of intracellular signaling."
  • Chiron Corporation Biotechnology Research Award, American Academy of Microbiology (2001). "For the development of systematic approaches to biology using small molecules."
  • Society for Biomolecular Screening Achievement Award (2004). "In recognition of the advances made in the field of chemical biology through the development and application of tools that enable the systematic use of small molecules to elucidate fundamental biological pathways."
  • American Association of Cancer Institutes (2004). "For his development of the field of chemical biology, which has resulted in a new approach to the treatment of cancer."

[edit] External links

[edit] Notes and references

  1. ^ "Calcineurin is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes" PubMed Jun Liu, Jesse D. Farmer, William S. Lane, Jeff Friedman, Irving Weissman, Stuart L. Schreiber, Cell 1991, 66, 807-815.
  2. ^ "Immunophilins, Ligands, and the Control of Signal Transduction" PubMed Stuart L. Schreiber, Gerald Crabtree Harvey Society Lectures 1997, 89, 373-380.
  3. ^ "Small Molecule Control of Insulin and PDGF Receptor Signaling and the Role of Membrane Attachment" PubMed Jian-xin Yang, Karen Symes, Mark Mercola, Stuart L. Schreiber, Curr Biol 1997, 8, 11-18.
  4. ^ "Probing the Role Of Homomeric And Heteromeric Receptor Interactions in TGF-β Signaling Using Small Molecule Dimerizers" PubMed Brent R. Stockwell and Stuart L. Schreiber, Curr. Biol, 1998, 8, 761-770.
  5. ^ "Functional Analysis of Fas Signaling in vivo Using Synthetic Dimerizers" David Spencer, Pete Belshaw, Lei Chen, Steffan Ho, Filippo Randazzo, Gerald R. Crabtree, Stuart L. Schreiber Curr. Biol. 1996, 6, 839-848.
  6. ^ "A Mammalian Protein Targeted by G1-Arresting Rapamycin-Receptor Complex" PubMed Eric J. Brown, Mark W. Albers, Tae Bum Shin, Kazuo Ichikawa, Curtis T. Keith, William S. Lane, Stuart L. Schreiber, Nature 1994, 369, 756-758.
  7. ^ "Dissection of a glucose-sensitive pathway of the nutrient-response network using diversity-oriented synthesis and small molecule microarrays" Finny G. Kuruvilla, Alykhan F. Shamji, Scott M. Sternson, Paul J. Hergenrother, Stuart L. Schreiber, Nature, 2002, 416, 653-656.
  8. ^ “Integration of the nutrient- and mitogen-regulated signaling networks: Implications for cancer biology” PubMed Alykhan F. Shamji, Paul Nghiem, Stuart L. Schreiber, Molecular Cell, 2003, 12, 271-280.
  9. ^ "A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p" PubMed Jack Taunton, Christian A. Hassig, Stuart L. Schreiber Science 1996, 272, 408-411.
  10. ^ "Signaling network model of chromatin”, PubMed Stuart L. Schreiber and Brad E. Bernstein, Cell, 2002, 111, 771-778.
  11. ^ (a) "Target-Oriented and Diversity-Oriented Organic Synthesis in Drug Discovery" PubMed Stuart L. Schreiber Science 2000, 287, 1964-1969. (b) "Generating diverse skeletons of small molecules combinatorially" PubMed M. D. Burke, E. M. Berger, S. L. Schreiber, Science, 2003, 302, 613-616. (c) "A planning algorithm for diversity-oriented synthesis", PubMed M. D. Burke, S. L. Schreiber, Angewandte Chemie, 2004, 43, 46-58.
  12. ^ "The small-molecule approach to biology: Chemical genetics and diversity-oriented organic synthesis make possible the systematic exploration of biology”, S L Schreiber, C&E News, 2003, 81, 51-61.
  13. ^ “From knowing to controlling: a path from genomics to drugs using small molecule probes"PubMed Robert L. Strausberg and Stuart L. Schreiber, Science, 2003, 300, 294-295.
  14. ^ "High-Throughput Screening of Small Molecules in Miniaturized Mammalian Cell-Based Assays Involving Post-Translational Modifications" PubMed Brent R. Stockwell, Stephen J. Haggarty, and Stuart L. Schreiber Chemistry & Biology 1999, 6, 71-83.
  15. ^ "Printing Small Molecules as Microarrays and Detecting Protein-Ligand Interactions en Masse" Gavin MacBeath, Angela N. Koehler, Stuart L. Schreiber J. Am. Chem. Soc. 1999, 121, 7967-7968.
  16. ^ “Printing proteins as microarrays for high throughput function determination” PubMed Gavin MacBeath and Stuart L. Schreiber Science, 2000, 289: 1760-1762.
  17. ^ "Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen" PubMed Thomas U. Mayer, Tarun M. Kapoor, Stephen J. Haggarty, Randall W. King, Stuart L. Schreiber, Timothy J. Mitchison Science 1999 286, 971-974.
  18. ^ "Small Molecules: The missing link in the central dogma" PubMed Stuart L. Schreiber, Nat. Chem. Biol., 2005, 1, 64-66.
Retrieved from "http://en.wikipedia.org../../../s/t/u/Stuart_Schreiber_956b.html"